QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
QQQ   303.59 (-0.85%)
AAPL   151.73 (-1.79%)
MSFT   256.77 (-0.61%)
META   186.06 (-0.25%)
GOOGL   102.90 (-1.79%)
AMZN   102.18 (-1.17%)
TSLA   194.76 (+2.52%)
NVDA   210.89 (-0.05%)
NIO   10.93 (-2.32%)
BABA   105.45 (-0.83%)
AMD   83.68 (-2.80%)
T   19.58 (-1.26%)
F   13.14 (-0.68%)
MU   59.98 (-3.89%)
CGC   2.95 (+1.03%)
GE   82.35 (+0.48%)
DIS   109.87 (-0.76%)
AMC   6.80 (+11.84%)
PFE   43.76 (-0.68%)
PYPL   82.33 (-3.73%)
NFLX   361.48 (-1.21%)
NASDAQ:NVCR

NovoCure - NVCR Stock Forecast, Price & News

$91.89
-2.33 (-2.47%)
(As of 02/6/2023 12:00 AM ET)
Add
Compare
Today's Range
$90.31
$94.55
50-Day Range
$67.94
$118.81
52-Week Range
$56.39
$120.03
Volume
612,911 shs
Average Volume
1.64 million shs
Market Capitalization
$9.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$111.86

NovoCure MarketRank™ Forecast

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
21.7% Upside
$111.86 Price Target
Short Interest
Bearish
7.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.14mentions of NovoCure in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$24.05 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.85) to ($1.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.71 out of 5 stars

Medical Sector

818th out of 1,027 stocks

Surgical & Medical Instruments Industry

87th out of 105 stocks

NVCR stock logo

About NovoCure (NASDAQ:NVCR) Stock

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Stock News Headlines

Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Why Novocure Stock Is Flying High
Why Novocure Stock Is Skyrocketing Today
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Novocure Stock: Bull vs. Bear
Novocure Secures CE Mark for New Array
2 Potentially Explosive Stocks to Buy in November
NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates
Novocure (NVCR) Q3 2022 Earnings Call Transcript
Why Novocure Stock Is Sinking Today
Novocure to Report Third Quarter 2022 Financial Results
See More Headlines
Receive NVCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter.

NVCR Company Calendar

Last Earnings
10/28/2021
Today
2/06/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVCR
Fax
N/A
Employees
1,167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$111.86
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+21.7%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-58,350,000.00
Pretax Margin
-13.80%

Debt

Sales & Book Value

Annual Sales
$535.03 million
Book Value
$3.95 per share

Miscellaneous

Free Float
98,422,000
Market Cap
$9.64 billion
Optionable
Optionable
Beta
0.82

Key Executives

  • Asaf DanzigerAsaf Danziger
    Chief Executive Officer & Director
  • Wilhelmus C. M. GroenhuysenWilhelmus C. M. Groenhuysen
    Chief Operating Officer
  • Ashley CordovaAshley Cordova
    Chief Financial Officer
  • Moshe Giladi
    Chief Science Officer
  • Piet Hinoul
    Senior Vice President & Head-Medical













NVCR Stock - Frequently Asked Questions

Should I buy or sell NovoCure stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVCR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View NVCR analyst ratings
or view top-rated stocks.

What is NovoCure's stock price forecast for 2023?

7 Wall Street analysts have issued 1 year price objectives for NovoCure's stock. Their NVCR share price forecasts range from $55.00 to $200.00. On average, they anticipate the company's share price to reach $111.86 in the next twelve months. This suggests a possible upside of 21.7% from the stock's current price.
View analysts price targets for NVCR
or view top-rated stocks among Wall Street analysts.

How have NVCR shares performed in 2023?

NovoCure's stock was trading at $73.35 at the beginning of the year. Since then, NVCR stock has increased by 25.3% and is now trading at $91.91.
View the best growth stocks for 2023 here
.

When is NovoCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NVCR earnings forecast
.

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, February 23rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) announced its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.07. The medical equipment provider had revenue of $133.61 million for the quarter, compared to the consensus estimate of $141.22 million. NovoCure had a negative trailing twelve-month return on equity of 18.85% and a negative net margin of 15.05%. The company's revenue for the quarter was up .7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.09 EPS.

What guidance has NovoCure issued on next quarter's earnings?

NovoCure issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $128.40 million-$128.40 million, compared to the consensus revenue estimate of $129.14 million.

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees.

What other stocks do shareholders of NovoCure own?
What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different institutional and retail investors. Top institutional investors include Nordwand Advisors LLC (8.68%), Baillie Gifford & Co. (8.45%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), New York State Common Retirement Fund (0.20%), Wolverine Asset Management LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends
.

How do I buy shares of NovoCure?

Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $91.91.

How much money does NovoCure make?

NovoCure (NASDAQ:NVCR) has a market capitalization of $9.65 billion and generates $535.03 million in revenue each year. The medical equipment provider earns $-58,350,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How many employees does NovoCure have?

The company employs 1,167 workers across the globe.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com.

This page (NASDAQ:NVCR) was last updated on 2/6/2023 by MarketBeat.com Staff